Sign in
Back
Comparison of the FDA-Approved CDC DENV-1-4 Real-Time Reverse Transcription-PCR with a Laboratory-Developed Assay for Dengue Virus Detection and Serotyping
Journal article   Open access  Peer reviewed

Comparison of the FDA-Approved CDC DENV-1-4 Real-Time Reverse Transcription-PCR with a Laboratory-Developed Assay for Dengue Virus Detection and Serotyping

Jesse J. Waggoner, Janaki Abeynayake, Malaya K. Sahoo, Lionel Gresh, Yolanda Tellez, Karla Gonzalez, Gabriela Ballesteros, Frances P. Guo, Angel Balmaseda, Kumudu Karunaratne, …
Journal of clinical microbiology, Vol.51(10), pp.3418-3420
01/10/2013
DOI: https://doi.org/10.1128/JCM.01359-13
PMCID: PMC3811623
PMID: 23903549

Abstract

Virology
Dengue virus (DENV) is the agent of the most common vector-borne disease worldwide. Using 199 clinical samples collected from Nicaragua and Sri Lanka, a laboratory-developed DENV multiplex real-time reverse transcription-PCR (rRT-PCR) proved more clinically sensitive than the FDA-approved CDC assay for DENV serotypes 1 to 4 when measured against a composite reference standard, with sensitivities of 97.4% versus 87.1%, respectively.
url
https://doi.org/10.1128/JCM.01359-13View
Published (Version of record) Open

Metrics

1 Record Views

Details